
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 3.090 | 3.260 | 0.170 |
Shares | 96.900 | 96.900 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 16.048 | 19.779 |
Price to Book | 4.337 | 4.043 |
Price to Sales | 4.385 | 2.422 |
Price to Cash Flow | 14.639 | 16.160 |
Dividend Yield | 1.480 | 1.381 |
5 Years Earnings Growth | 9.502 | 12.141 |
Number of long holdings: 66
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eli Lilly | US5324571083 | 7.00 | 867.05 | +1.15% | |
Merck&Co | US58933Y1055 | 5.35 | 85.60 | +2.77% | |
Roche Holding Participation | CH0012032048 | 4.79 | 294.70 | -0.07% | |
Regeneron Pharma | US75886F1075 | 4.36 | 685.66 | +0.83% | |
Thermo Fisher Scientific | US8835561023 | 4.33 | 530.86 | +1.49% | |
AstraZeneca | GB0009895292 | 4.06 | 11,704.0 | -0.71% | |
Novo Nordisk B | DK0062498333 | 4.03 | 597.5 | +1.79% | |
Amgen | US0311621009 | 3.99 | 294.27 | +0.50% | |
Gilead | US3755581036 | 3.89 | 107.65 | +2.28% | |
Hologic | US4364401012 | 3.68 | 64.20 | +0.42% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
LU2197358042 | 3.18B | 2.46 | 13.77 | - | ||
Cleome Index USA Equities R EUR Acc | 3.18B | 2.44 | 13.52 | 13.62 | ||
Cleome Index USA Equities Y EUR Acc | 3.18B | 2.35 | 12.32 | 12.73 | ||
Cleome Index USA Equities Z EUR Acc | 3.18B | 2.47 | 13.86 | 14.01 | ||
Candriam Equities L Global Demograp | 2.26B | 2.95 | 8.99 | 10.72 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review